Generated: August 23, 2017
DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 086162
describes BUTALBITAL, ASPIRIN AND CAFFEINE
, which is a drug marketed by Actavis Elizabeth, Watson Labs, Ivax Pharms, Halsey, Puracap Pharm, Nostrum Labs Inc, Hikma Intl Pharms, Quantum Pharmics, PII, and Sandoz, and is included in eleven NDAs. It is available from nine suppliers. Additional details are available on the BUTALBITAL, ASPIRIN AND CAFFEINE profile page.
The generic ingredient in BUTALBITAL, ASPIRIN AND CAFFEINE is aspirin; butalbital; caffeine. There are twenty-one drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the aspirin; butalbital; caffeine profile page.
Summary for NDA: 086162
|Formulation / Manufacturing:||see details|
Pharmacology for NDA: 086162
Complete Access Available with Subscription
Summary for product number 002
|Approval Date:||Feb 16, 1984||TE:||AA||RLD:||No|
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.